U.S. Intravenous Immunoglobulin Market Size, Share & Trends Report

U.S. Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Primary Immunodeficiency Diseases, Multifocal Motor Neuropathy), By Distribution Channel, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-2-68038-428-4
  • Number of Pages: 85
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2020
  • Industry: Healthcare

Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation and Scope
                       1.1.1 Regional scope
                       1.1.2 Estimates and forecast timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased database:
                       1.3.2 GVR’s internal database
                       1.3.3 Secondary sources
                       1.3.4 Primary research
                   1.4 Information or Data Analysis
                       1.4.1 Data analysis models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis (Model 1)
                           1.6.1.1 Approach 1: Commodity Flow Approach
                   1.7 Research Assumptions
                   1.8 List of Secondary Sources
                   1.9 List of Abbreviations
                   1.10 Objectives
                       1.10.1 Objective 1
                       1.10.2 Objective 2
                       1.10.3 Objective 3
                       1.10.4 Objective 4
Chapter 2 Executive Summary
                   2.1 Market Outlook
Chapter 3 U.S. Intravenous Immunoglobulin Market Variables, Trends, and Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent market outlook
                           3.1.1.1 Intravenous Immunoglobulin Market
                       3.1.2 Ancillary market outlook
                           3.1.2.1 Idiopathic Thrombocytopenic Purpura Therapeutics Market
                   3.2 Penetration and Growth Prospect Mapping for Application, 2022
                   3.3 Market Dynamics
                       3.3.1 Market Driver Analysis
                           3.3.1.1 Rising number of immunodeficiency disease cases
                           3.3.1.2 Rising adoption of immunoglobulin replacement therapies
                           3.3.1.3 Approval and launch of novel products
                           3.3.1.4 Increasing R&D investments
                       3.3.2 Market Restraint Analysis
                           3.3.2.1 Cost-intensive nature of immunoglobulin replacement therapy
                           3.3.2.2 Stringent regulations pertaining to production and approval
                       3.3.3 Industry Opportunities
                   3.4 Market Analysis Tools
                       3.4.1 Industry Analysis: Porter’s
                       3.4.2 PESTLE Analysis
                       3.4.3 Regulatory Scenario
                   3.5 COVID-19 Impact on U.S. Intravenous Immunoglobulin (IVIG) Market
Chapter 4 U.S. Intravenous Immunoglobulin Market: Application Segment Analysis
                   4.1 U.S. Intravenous Immunoglobulin Market: Application Movement Analysis
                   4.2 Market Size & Forecasts and Trend Analyses, 2018 to 2030
                       4.2.1 Primary Immune Deficiency
                           4.2.1.1 Primary Immune Deficiency Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                           4.2.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.3 Primary Immunodeficiency Diseases (PIDD)
                           4.2.3.1 Primary Immunodeficiency Diseases (PIDD) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.4 Congenital AIDS
                           4.2.4.1 Congenital AIDS Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.5 Chronic Lymphocytic Leukemia
                           4.2.5.1 Chronic Lymphocytic Leukemia Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.6 Myasthenia Gravis
                           4.2.6.1 Myasthenia Gravis Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.7 Multifocal Motor Neuropathy
                           4.2.7.1 Multifocal Motor Neuropathy Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.8 Immune Thrombocytopenic Purpura (ITP)
                           4.2.8.1 Immune Thrombocytopenia Purpura (ITP) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.9 Kawasaki Disease
                           4.2.9.1 Kawasaki Disease Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.10 Guillain-Barré Syndrome (GBS)
                           4.2.10.1 Guillain-Barré Syndrome (GBS) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       4.2.11 Others
                           4.2.11.1 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Chapter 5 U.S. Intravenous Immunoglobulin Market: Distribution Channel Segment Analysis
                   5.1 U.S. Intravenous Immunoglobulin Market: Distribution Channel Movement Analysis
                   5.2 Market Size & Forecasts and Trend Analyses, 2018 to 2030
                       5.2.1 Hospital Pharmacy
                           5.2.1.1 Hospital Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       5.2.2 Specialty Pharmacy
                           5.2.2.1 Specialty Pharmacy Market Estimates & Forecasts, 2018 - 2030 (USD Million)
                       5.2.3 Others
                           5.2.3.1 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Chapter 6 U.S. Intravenous Immunoglobulin Market: Regional Market Analysis, 2018 - 2030 (USD Million)
                   6.1 U.S.
                       6.1.1 U.S. Intravenous Immunoglobulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7 U.S. Intravenous Immunoglobulin Market - Competitive Analysis
                   7.1 Recent Developments and Impact Analysis, by Key Market Participants
                       7.1.1 New Product Launch
                       7.1.2 Acquisition
                       7.1.3 Collaboration & Expansion
                       7.1.4 Promotion & Awareness Campaign
                   7.2 Company Categorization
                       7.2.1 Innovators
                       7.2.2 Market Leaders
                   7.3 Vendor Landscape
                       7.3.1 List of key distributors and channel partners
                       7.3.2 Key customers
                   7.4 Public Companies
                       7.4.1 Company market position analysis
                       7.4.2 Competitive Dashboard Analysis
                       7.4.2.1 KEY COMPANY MARKET SHARE ANALYSIS, 2022
                       7.4.3 Market Differentiators
                   7.5 Private Companies
                       7.5.1 List of key emerging companies
                   7.6 Company Profiles
                       7.6.1 Biotest AG
                           7.6.1.1 Company overview
                           7.6.1.2 Financial performance
                           7.6.1.3 Product benchmarking
                           7.6.1.4 Strategic initiatives
                       7.6.2 Octapharma AG
                           7.6.2.1 Company overview
                           7.6.2.2 Financial performance
                           7.6.2.3 Product benchmarking
                           7.6.2.4 Strategic initiatives
                       7.6.3 LFB Biotechnologies S.A.S
                           7.6.3.1 Company overview
                           7.6.3.2 Product benchmarking
                           7.6.3.3 Strategic initiatives
                       7.6.4 China Biologics Products Holdings, Inc.
                           7.6.4.1 Company overview
                           7.6.4.2 Financial performance
                           7.6.4.3 Product benchmarking
                           7.6.4.4 Strategic initiatives
                       7.6.5 Grifols, S.A.
                           7.6.5.1 Company overview
                           7.6.5.2 Financial performance
                           7.6.5.3 Product benchmarking
                           7.6.5.4 Strategic initiatives
                       7.6.6 Kedrion S.p.A
                           7.6.6.1 Company overview
                           7.6.6.2 Financial performance
                           7.6.6.3 Product benchmarking
                           7.6.6.4 Strategic initiatives
                       7.6.7 CSL
                           7.6.7.1 Company overview
                           7.6.7.2 Financial performance
                           7.6.7.3 Product benchmarking
                           7.6.7.4 Strategic initiatives
                       7.6.8 Takeda Pharmaceutical Company Limited
                           7.6.8.1 Company overview
                           7.6.8.2 Shire plc
                           7.6.8.3 Financial performance
                           7.6.8.4 Product benchmarking
                           7.6.8.5 Strategic initiatives
                       7.6.9 Bio Products Laboratory Ltd.
                           7.6.9.1 Company overview
                           7.6.9.2 Product benchmarking
                           7.6.9.3 Strategic initiatives
                       7.6.10 Pfizer, Inc.
                           7.6.10.1 Company overview
                           7.6.10.2 Financial performance
                           7.6.10.3 Product benchmarking
                           7.6.10.4 Strategic initiatives
                       7.6.11 ADMA Biologics, Inc.
                           7.6.11.1 Company overview
                           7.6.11.2 Financial performance
                           7.6.11.3 Product benchmarking
                           7.6.11.4 Strategic initiatives


List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Leading market players anticipated to witness highest growth
Table 4 U.S. Intravenous Immunoglobulin Market, By Application, 2018 - 2030 (USD Million)
Table 5 U.S. Intravenous Immunoglobulin Market, By Distribution Channel, 2018 - 2030 (USD Million)


List of Figures

Fig. 1 U.S. intravenous immunoglobulin market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. intravenous immunoglobulin market snapshot
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook, revenue, 2022, (USD Million)
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. intravenous immunoglobulin market driver impact
Fig. 14 U.S. intravenous immunoglobulin market restraint impact
Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 16 Industry Analysis - Porter’s
Fig. 17 Strategy mapping
Fig. 18 U.S. intravenous immunoglobulin market: application outlook and key takeaways
Fig. 19 U.S. intravenous immunoglobulin market: application movement analysis & market share 2022 & 2030
Fig. 20 Primary immunodeficiency diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Immunodeficiency diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Congenital AIDS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Chronic lymphocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Myasthenia Gravis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Multifocal motor neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Immune Thrombocytopenia (ITP) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Kawasaki disease intravenous immunoglobulin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Guillain-Barre Syndrome intravenous immunoglobulin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Others intravenous immunoglobulin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 U.S. intravenous immunoglobulin market: distribution channel outlook and key takeaways
Fig. 32 U.S. intravenous immunoglobulin market: distribution channel movement analysis & market share 2022 & 2030
Fig. 33 Hospital pharmacy intravenous immunoglobulin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Specialty pharmacy intravenous immunoglobulin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Others intravenous immunoglobulin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 U.S. intravenous immunoglobulin: Regional outlook and key takeaways
Fig. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Ansoff Matrix
Fig. 39 Market differentiators
Fig. 40 Key company market share analysis, 2022
Fig. 41 Company market position analysis
Fig. 42 Competitive dashboard analysis

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon